Literature DB >> 12670921

Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.

Carol Sawyer1, Justin Sturge, Dorothy C Bennett, Michael J O'Hare, William E Allen, Jennifer Bain, Gareth E Jones, Bart Vanhaesebroeck.   

Abstract

Class IA phosphoinositide 3'-kinases (PI3Ks) regulate many cellular processes downstream of tyrosine kinases and Ras. Despite a clear implication of PI3K in cancer, little is known about the distribution of the different PI3K isoforms in malignant cells. We screened a large panel of tissues and cell lines for expression of class IA PI3Ks, and document a ubiquitous expression of the p110alpha and p110beta isoforms but a variable and more restricted tissue distribution of the p110delta isoform. Originally found in WBCs, p110delta was also detected in some nonhematopoietic cell types especially those of breast or melanocytic origin, both in the untransformed and transformed state. Isoform-specific neutralization of PI3K isoforms in breast cancer cell lines (by PI3K antibody microinjection or a p110delta-selective pharmacological inhibitor) demonstrated that p110delta is the most important class IA PI3K in the regulation of epidermal growth factor-driven motility in vitro, controlling the directionality and, to a lesser extent, the speed of migration. In contrast, p110beta was required for the direction but not the speed of migration, whereas p110alpha did not impact on either of these parameters. These results show a nonredundant function of PI3K isoforms downstream of the epidermal growth factor receptor and indicate that the presence of p110delta may confer breast cancer cells with selective migratory capacities. The potential clinical implications of p110delta expression in non-WBC-derived tumors are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670921

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  Activity of any class IA PI3K isoform can sustain cell proliferation and survival.

Authors:  Lazaros C Foukas; Inma M Berenjeno; Alexander Gray; Asim Khwaja; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 2.  Molecules in medicine mini-review: isoforms of PI3K in biology and disease.

Authors:  Bart Vanhaesebroeck; Maria A Whitehead; Roberto Piñeiro
Journal:  J Mol Med (Berl)       Date:  2015-12-10       Impact factor: 4.599

3.  Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.

Authors:  Sohye Kang; Adam Denley; Bart Vanhaesebroeck; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

4.  p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease.

Authors:  Aurore Saudemont; Fabien Garçon; Hakim Yadi; Marta Roche-Molina; Nayoung Kim; Anne Segonds-Pichon; Alfonso Martín-Fontecha; Klaus Okkenhaug; Francesco Colucci
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

Review 5.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

6.  Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis.

Authors:  Qi Shi; Thomas M Kaiser; Zackery W Dentmon; Mariangela Ceruso; Daniela Vullo; Claudiu T Supuran; James P Snyder
Journal:  ACS Med Chem Lett       Date:  2015-04-03       Impact factor: 4.345

Review 7.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

8.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

9.  Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells.

Authors:  Neil Kumar; Raffi Afeyan; Hyung-Do Kim; Douglas A Lauffenburger
Journal:  Mol Pharmacol       Date:  2008-03-18       Impact factor: 4.436

10.  Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.

Authors:  Bart M Maślikowski; Benjamin D Néel; Ying Wu; Lizhen Wang; Natalie A Rodrigues; Germain Gillet; Pierre-André Bédard
Journal:  BMC Cancer       Date:  2010-02-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.